Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting

Core Viewpoint - Zentalis Pharmaceuticals is advancing its clinical-stage biopharmaceutical development of azenosertib, a WEE1 inhibitor, with a poster presentation scheduled at the 2025 ASCO Annual Meeting, showcasing its potential in treating metastatic colorectal cancer and other tumor types [1][2][4]. Company Overview - Zentalis Pharmaceuticals, Inc. is focused on developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor targeting Cyclin E1+ platinum-resistant ovarian cancer and other tumor types [4]. - The company is conducting clinical trials to evaluate azenosertib both as a monotherapy and in combination therapies, demonstrating anti-tumor activity and good tolerability across various cancer types [4]. Clinical Trial Details - An abstract has been accepted for a poster presentation at the 2025 ASCO Annual Meeting, detailing the Phase 1/2 clinical trial results of azenosertib in combination with encorafenib and cetuximab for patients with metastatic BRAF V600E mutant colorectal cancer [2]. - The poster presentation is scheduled for May 31, 2025, and will include clinical data up to an April 4, 2025 cutoff [2]. Mechanism of Action - Azenosertib functions as a selective and orally bioavailable WEE1 inhibitor, which regulates the G1-S and G2-M cell cycle checkpoints, allowing for cell cycle progression despite DNA damage, ultimately leading to cancer cell death [3].